Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
NYBC Ventures, launched in 2021 by New York Blood Center Enterprises (NYBCe), manages a $50 million fund based in Boston, Massachusetts. The firm leverages over 60 years of experience in blood products and transfusion services, supported by the Lindsley F. Kimball Research Institute (LFKRI), known for its foundational research.
NYBC Ventures invests in early to mid-stage companies focusing on blood and cellular therapies, including therapeutics and devices. Their investment strategy targets solutions addressing challenges in hematology, transfusion medicine, and infectious diseases.
Submit through their form at nybcventures.com.
Yes, NYBC Ventures often leads investment rounds, particularly in their focus areas of blood and cellular therapies.
NYBC Ventures is open to follow-on investments, especially for companies that align with their mission in healthcare innovation.
NYBC Ventures currently manages a fund size of $50 million, dedicated to early to mid-stage investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.